Want to see ARMP full AI Analyst Report?
Top Page
Armata Pharmaceuticals
(ARMP)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.00
▼(-28.06% Downside)
Action:Reiterated
Date:09/23/26
The score is held down primarily by weak financial performance (persistent losses, negative equity, and cash burn) and a bearish technical setup (below major moving averages with negative momentum). Offsetting this somewhat are notable positive corporate events—Breakthrough Therapy designation and incremental non-dilutive Phase 3 funding—which improve program momentum and reduce funding pressure, but do not fully counterbalance the current financial and trend risks.
Positive Factors
Non-dilutive Phase 3 funding
The additional non-dilutive funding directly supports AP-SA02’s Phase 3 execution while reducing reliance on equity financing. Continued U.S. government backing also validates the program’s strategic importance and can extend development runway as Armata advances toward pivotal clinical testing.
Negative Factors
Negative equity and leverage
Negative stockholders’ equity and meaningful debt leave Armata with limited balance-sheet resilience while its programs remain in development. This weak financial foundation can restrict strategic flexibility and increase dependence on future financing or partner support.
Read all positive and negative factors
Positive Factors
Negative Factors
Non-dilutive Phase 3 funding
The additional non-dilutive funding directly supports AP-SA02’s Phase 3 execution while reducing reliance on equity financing. Continued U.S. government backing also validates the program’s strategic importance and can extend development runway as Armata advances toward pivotal clinical testing.
Read all positive factors
Armata Pharmaceuticals (ARMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$134.97M
Dividend YieldN/A
Average Volume (3M)274.96K
Price to Earnings (P/E)―
Beta (1Y)0.42
Revenue Growth-19.29%
EPS Growth-645.64%
CountryUS
Employees61
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.30
Shares Outstanding37,181,980
10 Day Avg. Volume95,152
30 Day Avg. Volume274,958
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)46.41
P/FCF Ratio-8.65
Enterprise Value/Market Cap5.13
Enterprise Value/Revenue209.77
Enterprise Value/Gross Profit307.43
Enterprise Value/Ebitda-4.10
Forecast
1Y Price Target
$17.50Price Target Upside214.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.62
Revenue Forecast (FY)$3.00M
Armata Pharmaceuticals Business Overview & Revenue Model
Company Description
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard ant...
How the Company Makes Money
As a clinical-stage biotechnology company, Armata Pharmaceuticals does not primarily generate recurring revenue from commercial product sales because its product candidates are in development and may not be approved for marketing. The company’s fu...
Armata Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.30M | 4.90M | 5.17M | 4.53M | 5.51M | 4.47M |
| Gross Profit | 2.25M | 3.37M | -29.25M | 3.56M | -29.51M | -15.54M |
| EBITDA | -168.97M | -155.68M | -6.85M | -65.45M | -36.00M | -21.92M |
| Net Income | -192.18M | -173.80M | -18.92M | -69.05M | -36.92M | -23.16M |
Balance Sheet | ||||||
| Total Assets | 89.95M | 76.88M | 86.44M | 98.36M | 107.88M | 69.77M |
| Cash, Cash Equivalents and Short-Term Investments | 23.95M | 8.69M | 9.29M | 13.52M | 14.85M | 10.29M |
| Total Debt | 313.95M | 288.02M | 126.52M | 120.37M | 48.81M | 37.99M |
| Total Liabilities | 321.12M | 295.48M | 134.46M | 130.43M | 71.80M | 44.37M |
| Stockholders Equity | -231.17M | -218.60M | -48.02M | -32.06M | 36.08M | 25.40M |
Cash Flow | ||||||
| Free Cash Flow | -25.79M | -26.30M | -39.43M | -55.57M | -34.69M | -24.88M |
| Operating Cash Flow | -25.42M | -25.76M | -37.55M | -47.42M | -32.48M | -23.57M |
| Investing Cash Flow | -374.00K | -542.00K | -1.88M | -8.13M | -2.21M | -1.30M |
| Financing Cash Flow | 44.15M | 25.61M | 34.96M | 53.99M | 44.02M | 25.52M |
Armata Pharmaceuticals Technical Analysis
Negative
5.56
Price Trends
4.59
Negative
5.49
Negative
7.25
Negative
Market Momentum
-0.32
Negative
39.59
Neutral
61.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARMP, the sentiment is Negative. The current price of 5.56 is above the 20-day moving average (MA) of 3.92, above the 50-day MA of 4.59, and below the 200-day MA of 7.25, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 39.59 is Neutral, neither overbought nor oversold. The STOCH value of 61.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARMP.
Armata Pharmaceuticals Risk Analysis
Armata Pharmaceuticals disclosed 30 risk factors in its most recent earnings report. Armata Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Armata Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $69.88M | 8.64 | 16.17% | 0.52% | 26.04% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $125.20M | -0.55 | -68.99% | ― | 196.02% | 98.71% | |
46 Neutral | $134.97M | -0.69 | 89.70% | ― | -19.29% | -645.64% | |
44 Neutral | $118.91M | -0.96 | -1005.80% | 0.36% | -100.00% | 54.89% |
* Healthcare Sector Average
ARMP
Armata Pharmaceuticals
3.63
0.33
10.00%
INO
Inovio Pharmaceuticals
1.15
-1.32
-53.44%
TNXP
Tonix Pharma
7.30
-12.76
-63.61%
SPRO
Spero Therapeutics
1.20
-1.09
-47.60%
Armata Pharmaceuticals Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Armata secures new U.S. funding for AP-SA02 Phase 3
Positive
Sep 23, 2026
On September 23, 2026, Armata Pharmaceuticals announced it received an additional $3.7 million in non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02, its intravenously administered multi-phage candidate ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Armata wins FDA Breakthrough Therapy for AP-SA02
Positive
Sep 14, 2026
On September 14, 2026, Armata Pharmaceuticals announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to AP‑SA02, its intravenously administered multi‑phage product candidate for adjunct treatment ...
Executive/Board Changes
Armata Pharmaceuticals Promotes David House to CFO
Neutral
Jul 20, 2026
On July 17, 2026, Armata Pharmaceuticals’ board promoted David House to Chief Financial Officer, formalizing his role through a new employment letter agreement that took effect the same day. House, who had served as Senior Vice President, Fi...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Armata Advances AP-SA02 Toward Phase 3 Trial Launch
Positive
Jul 20, 2026
On July 20, 2026, Armata Pharmaceuticals reported notable progress across clinical, regulatory and manufacturing activities for AP-SA02, its intravenously administered multi-phage candidate for complicated Staphylococcus aureus bacteremia caused b...
Business Operations and StrategyRegulatory Filings and Compliance
Armata Advances AP-SA02 Pediatric Plan With FDA Agreement
Positive
Jul 13, 2026
On July 13, 2026, Armata Pharmaceuticals announced that the U.S. Food and Drug Administration had agreed to the company’s Initial Pediatric Study Plan for AP-SA02 as an adjunct treatment for complicated Staphylococcus aureus bacteremia in pa...
Business Operations and StrategyPrivate Placements and Financing
Armata gains new DoD funding for AP-SA02 advancement
Positive
Jun 23, 2026
On June 23, 2026, Armata Pharmaceuticals announced it received an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense, bringing total DoD support to $28.7 million for its lead candidate AP-SA02. The bacteriophage-ba...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.